Ribbon Bio Appoints Jeff Fitzgerald as Vice President, Global Head of Sales to Drive Commercial Growth and Strategic Expansion
VIENNA--(BUSINESS WIRE)--Ribbon Bio GmbH, the DNA synthesis company, today announced that Jeff Fitzgerald has joined the company as Vice President, Global Head of Sales. With a proven track record in scaling commercial operations and leading teams across the industry, Mr. Fitzgerald will take on a pivotal role in accelerating Ribbon Bio's next phase of growth.
'We're thrilled to welcome Jeff to the Ribbon Bio leadership team at this important time, as we commence our exciting first product launch with MiroSynth™ DNA Molecules,' said Jodi Barrientos, CEO.
Reporting directly to Jodi Barrientos, Ribbon's CEO, Mr. Fitzgerald will oversee all aspects of global sales strategy, business development, and market expansion as the company commercializes its technology to produce pristine synthetic DNA molecules to serve advanced applications in biopharma and life sciences.
'We're thrilled to welcome Jeff to the Ribbon Bio leadership team at this important time, as we commence our exciting first product launch with MiroSynth™ DNA Molecules,' said Ms. Barrientos. 'His deep industry experience and customer-first approach make him the ideal leader to help drive our commercial strategy forward, especially as global demand for more complex and highly accurate synthetic DNA continues to rise.'
Mr. Fitzgerald brings more than a decade of successful commercial leadership experience in life science companies, including executive roles at ArcherDx (acquired by Integrated DNA Technologies (IDT)), and IQVIA (formerly Quintiles), where he led high-performing teams, delivered sustained revenue growth across multiple geographies, and supported commercial integrations post-merger and acquisition. His expertise in product launches, building strategic partnerships and scaling go-to-market operations aligns well with Ribbon Bio's mission to redefine what's possible in synthetic biology through precision-engineered DNA.
'I'm very excited to join Ribbon Bio at such a transformative moment,' said Mr. Fitzgerald. 'The company's ability to deliver highly complex and accurate synthetic DNA is unmatched—and I'm looking forward to supporting our partners to bring their most ambitious biological designs to life with MiroSynth™ DNA Molecules.'
MiroSynth™ DNA is built on Ribbon's proprietary algorithm-driven technology and precision enzymatic assembly process, delivering exceptional accuracy and performance for applications initially in biopharma, life sciences, and academic research. Customers and partners across the US, EU, UK, and Australia can now access MiroSynth™ DNA to accelerate their most ambitious scientific work.
This strategic hire follows a year of significant momentum for Ribbon Bio, including key leadership additions, major partnerships in biopharma and life sciences, demonstrated technical advances in its core platform, and growing global demand for synthetic DNA at the highest levels of complexity and precision.
About Ribbon Bio
Ribbon Bio is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies: making the impossible possible. We are redefining scientific possibility with our algorithm-driven technology that produces pristine synthetic DNA molecules, at a high level of accuracy and unprecedented speed, enabling our partners to deliver a new generation of transformative solutions for the health of people and the planet. For more information, visit us at www.ribbonbio.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
An AI bot might be asking the questions at your next job interview
When Wafa Shafiq realized her upcoming job interview would be conducted by an artificial intelligence bot, she thought: Why not? "I thought it'd be really cool. I wanted to try it," said Shafiq. Alex, an AI bot powered by software company Aprioria, interviewed the 26-year-old from Mississauga, Ont., for a marketing position at a retirement insurance agency. It asked her about herself and her experience for 30 minutes. It acknowledged her responses and complimented them before asking a followup question. "I was shocked that it was asking such good followup questions," Shafiq told CBC News. "My expectations had been lower." While some companies are turning to artificial intelligence to streamline their recruitment processes, some job candidates are concerned about how they're being evaluated and losing the chance to connect with recruiters. WATCH | How AI is changing the job interview process: This technology is still in the early phase, says Mike Shekhtman, senior regional director at Canadian employment agency Robert Half. "As the technology improves, we will continue to see perhaps an acceleration." Ribbon, an AI-interviewer software company, is among the Canadian companies to have seen an opportunity in this market. "A year ago, people thought we were crazy," Arsham Ghahramani, Ribbon's CEO, said in an interview. In nine months, Ribbon has amassed 400 customers who now use its bot to conduct interviews. Ghahramani and his team spent more than a year building and training their AI using publicly available interviews and voice datasets. They wanted their AI to show the right emotion and ask the right questions, he said. But some candidates would prefer a human recruiter. Maureen Green, a health technology consultant, was approached to do an interview for a position in a Canadian health-care company that uses AI to direct patient calls. She was told the interview would be done by the company's own AI bot. At first, Green, who lives in Vancouver, said she was impressed by the system, finding it spoke and acted similarly to a human. "It really did feel like a conversation and it felt like it was listening." But what was scheduled to be a 30-minute interview ended up going for more than an hour, as the AI kept asking followup questions and showed no signs of drawing the interview to an end. Not knowing what else to do, Green said she thanked the AI interviewer for its time. "I said: 'I'm so sorry, but it was wonderful talking to you. Thank you so much for the opportunity,' and so it ended." LISTEN | Are we ready for robots among us?: Green thought she had done well in the interview, but she never heard back. "I had been left feeling taken advantage of because … I put a lot of effort into this interview and really took it seriously, but I also get the feeling that it's being trained by talking to people," she said. "It can be done well, I'm sure, but this wasn't it." Shafiq shared the sentiment. She entered her interview with curiosity and some skepticism. The email she received to schedule the interview didn't mention AI — she only found out after looking into it herself. And she didn't get a followup after the interview either. She thought it was "cool" that she could schedule the interview at any time of the day, even in the middle of the night, and was impressed by the few glitches she experienced — it only had difficulty answering some of her questions. But she wished she had more information on how her performance would be evaluated. "If companies do use AI for recruitment, there's such an opportunity for communicating what the benefits of it are," Shafiq said. "Sending a message beforehand to be like: 'This is what to expect, this is how to prepare.'" Although Shafiq is open to doing more AI interviews, she said she missed the human connection she usually gets with regular interviews. "There's no small talk, there was nothing personal and I wasn't able to really tell if my answers were landing or not." Is it a replacement for human recruiters? Job interviews done by AI agents allow for much more flexibility in hiring internal roles and can accelerate the process, said Elena McGuire, director of people and special projects at Thrive Career Wellness, a Toronto-based HR consulting company. The company has several positions open at once and they hire internationally. They use Ribbon, which allows candidates to choose an interview time that works for them and to interview in French for bilingual positions. McGuire said it allowed the company to cut down thousands of applicants and hire six new employees. "It's really not meant to replace us HR folk, but help us." McGuire also said that the company's hiring decisions aren't made by AI. Ribbon summarizes interviews and gives scores based on the company's requirements, allowing recruiters to decide whether or not to move ahead with the candidate. "They're [companies] looking at ways to not lose any beat and not miss out on candidates," said Shekhtman, of employment agency Robert Half. "But that comes with a tremendous amount of caution as well," he added, to ensure AI agents don't overlook qualified candidates or spotlight unqualified ones by focusing too much on technicalities. But companies will ultimately leverage any tool that will help them streamline their processes, especially if their resources are waning, said Shekhtman. "If you don't embrace [the technology], you're going to get run over by it." When it comes to being interviewed by AI, Terri Griffith, Keith Beedie chairholder in innovation and entrepreneurship at Simon Fraser University in British Columbia, said she hasn't heard yet "a candidate be excited." She said AI is being used by both recruiters and applicants. "This is a punchline to a joke that goes: 'I used my AI to apply for the job, they used AI to review my application … now we're having an [AI] interview.'" LISTEN | What AI means for the future of your career: Griffith sees the use of AI bots in interviews having various potential outcomes: with enough pushback could come regulation or with enough improvement of the technology and its implementation could come approval. Green, reflecting on her interview, noted that although she is "really open" to AI, many people are not, and she hopes companies will understand that their trust needs to be earned. "I don't think we need to be speedy in applying these systems to what we are doing. I think we should be thoughtful and respectful of the people it's interacting with," she said. "So hopefully that will change, but I'm optimistic." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Yahoo
15 hours ago
- Yahoo
Development booming for Rochester's neighbors
May 31—ROCHESTER — Just north of Pine Island on the east side of U.S. Highway 52 lies about 400 acres in the township that, if all goes well over the next year or two, should become the future economic engine of the city. In March, the city started the environmental process that would lead to the annexation of that property — now mostly farmland — with the purpose of having a developer — Minneapolis-based Ryan Companies — turn that land into an industrial and technology business park. It's a project that could bring hundreds of jobs — not counting the construction jobs — long-term to the city. How did this happen? As the old saying goes with real estate deals, it's all about location. And in this case, the booming growth of nearby Rochester is one major factor. "The proximity to Rochester is a major factor to us," said Peter Fitzgerald, vice president of real estate development for Ryan Companies. Fitzgerald listed off Pine Island's attributes. In addition to proximity to Rochester there's also a quality workforce, proximity to the Twin Cities, and quick access to major highways such as Interstate 90, Highway 52 and Intestate 35. For Fitzgerald, the idea of developing along Highway 52 between the Twin Cities and Rochester goes back to his days, oddly enough, playing for the Rochester Honkers more than 20 years ago. Back in those days, he often drove between Rochester and the Twin Cities, a drive he felt was closer and quicker than people realized. So when he began working for Ryan Companies, he remembered that drive. "Highway 52 connects the first, second and third largest cities in the state of Minnesota," he said. "It made a ton of sense to pay attention to what's happening along Highway 52." Ryan Companies has been in the development business for 85 years in Minnesota, and has worked on projects around the state. The company has many developed projects in the Twin Cities and along I-35, Fitzgerald said. So, in evaluating Pine Island he saw good infrastructure such as utilities, available land, a strong and skilled workforce, and that access to highways and three major cities. "We had nothing along Highway 52, which we thought was a miss," he said. On the north end of Stewartville, the Schumann Business Park is filling up quickly. Mayor Jimmie-John King said that's because the land is "shovel ready" for development. "When you're putting up a $100 million building — no matter how rich you think people are — people don't want to screw around for 18 months on that borrowed money," King said, referring to the estimated investment in construction by United Therapeutics, a pig-to-human transplant facility. "(United Therapeutics) figures, working with us, they'll be ready to roll a year earlier than they planned on." King said that's a big benefit to companies, having roads, sewer and water and other utilities ready to connect to a site. "That's a huge benefit to these companies that come here," he said. He pointed to Stewartville's other big deal announced this year: Amazon will build a "last mile" delivery hub in Stewartville. With the site ready to build on, he said, a company could go from signing a development deal to beginning construction in as little as 90 days. In fact, real discussions with Amazon began in January, and, if a recent week of rain hadn't occurred, he said, the company would "already be digging in the dirt." United Therapeutics and Amazon are just the latest additions to the business park, first developed in 2003, that already includes Kwik Trip, Schwickert's Construction and FedEx Ground among others. And Schumann's isn't the only area that was built to be builder-ready. Tebay's Industrial Park a few blocks to the south on Highway 63 includes manufacturers Jimmy's Salad Dressings, Halcon Furniture and Geotek Inc. All, King said, have recently expanded or have plans to expand their building footprints, and that means more jobs coming to Stewartville. Elizabeth Howard, Pine Island's city administrator, said while the Ryan Companies development is still in the early stages, site planning would indicate room for 100 to 200 jobs coming to the city. That doesn't include construction jobs for developing the site. Despite the positives of the proposed deal, Howard said she's holding back on any celebrations. Pine Island, she said, has heard it before. "I still hear it in every single meeting I go to," said Howard, referring to the never-realized Elk Run bioscience development proposed by Tower Investments in the late 2000s and early 2010s. "It's at the top of people's minds." Howard said Ryan Companies isn't Tower Investments — which is a good thing — but as this proposal works its way into the environmental review process, she's "being more hesitant that the city is dotting its I's and crossing T's with the developer." Still, there is optimism in town. In April, the city hosted a town hall meeting where the public could come and ask questions about the proposal. "It went well," said Howard. "It was positive. The crowd was mainly people living around the project, more township folks than city folks. The developer and engineer were able to answer their questions and concerns." One question has been why Pine Island? In addition to the reasons listed by Fitzgerald, Howard said the power substation on the north end of town was a plus since data centers or technology businesses are envisioned as potential tenants. Right now, Fitzgerald said, Ryan Companies isn't thinking about end users as much as it is thinking about the environmental review — which should take most of the rest of 2025 — and pre-construction issues such as permitting and zoning. "It's looking at the magnitude of this development and taking a look at what mitigations should be in place to allow for this development," he said. Once all the pre-construction work is done, then Ryan Companies will start lining up tenants for the site. Fitzgerald said all that will take time. Development of the 400-plus acres will likely take a decade in total as more businesses buy up lots within the tech park on what will become the north end of Pine Island. "You do need an anchor tenant," he said. "We'll look for that anchor tenant who will kick off that development." Ron Zeigler, CEO of Community and Economic Development Associates, the economic development arm behind many communities in Southeast Minnesota, said, "Rochester needs a strong surrounding area, and the area needs a strong Rochester." What's happening in Stewartville and Pine Island, he said, is happening to some degree in just about every community near Rochester. "Every town is doing things to make themselves ready for housing development, business development," he said. Howard said Ryan Companies first approached Pine Island about 18 months ago. After some initial inquiries, she heard nothing for a few months. "I was cautious," she said. After all, the city and it's economic development team talk to developers often. But eventually, things started to fall into place. Howard said she got the right people talking to one another: decision makers, state agencies and the city. With so many hoops to jump through for even the most motivated city and developer, as city administrator she didn't want to "put the cart before the horse." "Don't spend taxpayer dollars inappropriately," she said. That means don't get overextended on roads or utilities. Talk to the school district and keep them in the loop. Have a plan for housing. That last one can be worked on no matter what. Both Olmsted County and Goodhue County have done studies showing the need for more housing — apartments, single-family, affordable, senior housing — enough so that she's not worried about pushing too far on that front. The city is already working on quality of life issues such as parks. And Pine Island has joined with neighboring towns — Zumbrota, Goodhue and Wanamingo — to develop a regional wastewater treatment cooperative. Stewartville City Administrator Bill Schimmel said his city — just with it's two newest development announcements, Amazon and United Therapeutics — that the city is looking at somewhere between 100 and 130 new permanent jobs. That doesn't include existing businesses — Halcon, Jimmy's and Geotek — that have or will be adding new jobs. Mayor King said that even on manufacturing lines, those jobs take skills which means those are good-paying jobs. Schimmel said the city is always looking to extend current development opportunities, whether that be residential or commercial/industrial. Apartments have been built in recent years, and roughly three dozen single-family home lots are available. As for business opportunities, there's still room for Schumann's Business Park to expand, but the city is also talking to landowners — including one on the north side of Interstate 90 — for new areas of development. After all, Stewartville is something of a business hotspot. "What seems to have happened, once some of these names are on our map, there seems to be inquiries," Schimmel said. Added King: "I think what we're going to see, and we're already seeing some of it, is the secondary-type business: truck repair shops, the support network. We're starting to hear from some of those type of people. There's a lot of opportunities that way." Opening up a shop that has oil filters and other routine maintenance parts for all those Amazon trucks, he said, would be a smart plan. For Pine Island, the payoff is a little farther down the road, but Howard said she sees it coming. And, like Stewartville has discovered, success can breed more success. "I hope that this is just the tip of the iceberg," Howard said. "I hope this is our new and improved Pine Island."
